SIREN : 807679386
MERIBEL PHARMA PESSAC is a French company founded 11 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in PESSAC (33600), this company of category ETI shows in 2024 a revenue of 17.6 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17 576 259 € | 14 800 569 € | 12 791 904 € | 12 871 067 € | 12 280 167 € | 10 414 749 € | 10 501 823 € | 10 258 242 € | 8 878 651 € |
| Net income | 842 805 € | -3 160 855 € | -1 116 926 € | -1 036 141 € | -2 030 379 € | -427 027 € | 98 060 € | 1 487 653 € | 1 846 580 € |
| EBITDA | 4 134 841 € | -1 920 264 € | -1 177 802 € | -1 694 401 € | -2 987 203 € | -2 152 920 € | -1 221 393 € | -1 391 911 € | -2 098 587 € |
| Net margin | 4.8% | -21.4% | -8.7% | -8.1% | -16.5% | -4.1% | 0.9% | 14.5% | 20.8% |
In 2024, MERIBEL PHARMA PESSAC achieves revenue of 17.6 M€. Over the period 2015-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +7.9%. Vs 2023, growth of +19% (14.8 M€ -> 17.6 M€). After deducting consumption (1.1 M€), gross margin stands at 16.5 M€, i.e. a rate of 94%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 4.1 M€, representing 23.5% of revenue. Positive scissor effect: EBITDA margin improves by +36.5 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 843 k€, i.e. 4.8% of revenue. This profit can be retained or distributed to shareholders.
17 576 259 €
16 456 898 €
4 134 841 €
1 391 563 €
842 805 €
23.1%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 80%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 20.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.0%
79.597%
20.946%
0.0
68.2%
In 2024, the debt ratio of MERIBEL PHARMA PESSAC (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of MERIBEL PHARMA PESSAC (79.6%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2024, the repayment capacity of MERIBEL PHARMA PESSAC (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 249.00. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 17.8x. Operating income very largely covers interest expenses: high safety margin.
248.999
17.847
In 2024, the liquidity ratio of MERIBEL PHARMA PESSAC (249.00) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of MERIBEL PHARMA PESSAC (17.9x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 19 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 61 days. Excellent situation: suppliers finance 42 days of the operating cycle (retail model). Inventory turnover is 107 days (= Average inventory / Cost of goods x 360). This high level ties up cash and potentially creates obsolescence risk. Overall, WCR represents 49 days of revenue, i.e. 2.4 M€ to permanently finance. Over 2015-2024, WCR increased by +122%, requiring additional financing.
2 385 626 €
19 j
61 j
107 j
49 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 168 155€ to 516 845€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare MERIBEL PHARMA PESSAC with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of MERIBEL PHARMA PESSAC in 2024 is 17.6 M€.
Yes, MERIBEL PHARMA PESSAC generated a net profit of 843 k€ in 2024.
The headquarters of MERIBEL PHARMA PESSAC is located in PESSAC (33600), in the department Gironde.
The tax return of MERIBEL PHARMA PESSAC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
MERIBEL PHARMA PESSAC operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.